Dr. Trněný, a professor of medical oncology at Charles University Hospital in Prague, discusses results from the phase 3 inMIND study.
The phase 3 trial enrolled patients with relapsed or refractory (R/R) follicular lymphoma who had failed at least one prior line of therapy. Patients were randomized to receive the standard regimen of lenalidomide plus rituximab (R²) with placebo, or the experimental regimen of R² plus tafasitamab.
The study met its primary endpoint of progression-free survival. By investigator assessment, the experimental arm showed a 57% reduction in the risk of progression or death (median PFS, 22 months versus 14 months for control). Median PFS in the experimental arm was not reached, compared with 16 months in the control arm, according to Dr. Trněný.
The inMIND study is a double-blind, placebo-controlled, randomized study investigating whether tafasitamab and lenalidomide as an add-on to rituximab provide improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R follicular lymphoma or marginal zone lymphoma.
